Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.3
(-3.54%)
SEK 0.3
(-3.54%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.76 Million SEK | -27.03% |
| 2022 | 36.67 Million SEK | -30.51% |
| 2021 | 52.78 Million SEK | 109.82% |
| 2020 | 25.15 Million SEK | 56.88% |
| 2019 | 16.03 Million SEK | -65.17% |
| 2018 | 46.03 Million SEK | 49.24% |
| 2017 | 30.84 Million SEK | 31.5% |
| 2016 | 23.45 Million SEK | 645.68% |
| 2015 | 3.14 Million SEK | -14.75% |
| 2014 | 3.69 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 11.81 Million SEK | -55.87% |
| 2024 Q2 | 41.4 Million SEK | 250.56% |
| 2024 Q3 | 28.59 Million SEK | -30.93% |
| 2023 Q2 | 22.99 Million SEK | -5.88% |
| 2023 Q1 | 24.43 Million SEK | -33.38% |
| 2023 FY | 26.76 Million SEK | -27.03% |
| 2023 Q4 | 26.76 Million SEK | 67.43% |
| 2023 Q3 | 15.98 Million SEK | -30.5% |
| 2022 FY | 36.67 Million SEK | -30.51% |
| 2022 Q4 | 36.67 Million SEK | -6.99% |
| 2022 Q3 | 39.43 Million SEK | 5.87% |
| 2022 Q2 | 37.25 Million SEK | -12.99% |
| 2022 Q1 | 42.81 Million SEK | -18.89% |
| 2021 Q4 | 52.78 Million SEK | 313.52% |
| 2021 Q1 | 10.15 Million SEK | -59.64% |
| 2021 Q2 | 20.92 Million SEK | 106.12% |
| 2021 FY | 52.78 Million SEK | 109.82% |
| 2021 Q3 | 12.76 Million SEK | -39.01% |
| 2020 Q2 | 49.04 Million SEK | -23.9% |
| 2020 Q1 | 64.45 Million SEK | 301.92% |
| 2020 Q3 | 39.84 Million SEK | -18.76% |
| 2020 Q4 | 25.15 Million SEK | -36.87% |
| 2020 FY | 25.15 Million SEK | 56.88% |
| 2019 Q3 | 26.79 Million SEK | -16.06% |
| 2019 Q1 | 38.2 Million SEK | -17.01% |
| 2019 FY | 16.03 Million SEK | -65.17% |
| 2019 Q4 | 16.03 Million SEK | -40.14% |
| 2019 Q2 | 31.91 Million SEK | -16.46% |
| 2018 Q1 | 22.62 Million SEK | -26.66% |
| 2018 FY | 46.03 Million SEK | 49.24% |
| 2018 Q4 | 46.03 Million SEK | -10.49% |
| 2018 Q3 | 51.43 Million SEK | -12.59% |
| 2018 Q2 | 58.83 Million SEK | 160.05% |
| 2017 Q3 | 43.21 Million SEK | -11.2% |
| 2017 Q4 | 30.84 Million SEK | -28.62% |
| 2017 FY | 30.84 Million SEK | 31.5% |
| 2017 Q1 | 65.35 Million SEK | 178.6% |
| 2017 Q2 | 48.66 Million SEK | -25.53% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 23.45 Million SEK | 0.0% |
| 2016 FY | 23.45 Million SEK | 645.68% |
| 2015 FY | 3.14 Million SEK | -14.75% |
| 2014 FY | 3.69 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| NextCell Pharma AB | 81.28 Million SEK | 67.076% |
| Biovica International AB (publ) | 131.4 Million SEK | 79.634% |
| Abliva AB (publ) | 87.49 Million SEK | 69.413% |
| Active Biotech AB (publ) | 44 Million SEK | 39.175% |
| Aptahem AB (publ) | 63.02 Million SEK | 57.536% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 77.406% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.089% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.744% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 56.939% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.592% |
| Cantargia AB (publ) | 223.71 Million SEK | 88.037% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -79.992% |
| CombiGene AB (publ) | 120.61 Million SEK | 77.811% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 96.479% |
| Fluicell AB (publ) | 9.34 Million SEK | -186.542% |
| Genovis AB (publ.) | 288.85 Million SEK | 90.735% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.371% |
| Mendus AB (publ) | 755.95 Million SEK | 96.46% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.873% |
| LIDDS AB (publ) | 17.65 Million SEK | -51.589% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 36.216% |
| Saniona AB (publ) | 64.14 Million SEK | 58.276% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 49.489% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 57.095% |
| Xintela AB (publ) | 18.39 Million SEK | -45.491% |
| Amniotics AB (publ) | 26.08 Million SEK | -2.595% |
| Corline Biomedical AB | 100.1 Million SEK | 73.265% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 11.302% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 92.382% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 84.89% |
| Intervacc AB (publ) | 259.61 Million SEK | 89.691% |
| Kancera AB (publ) | 65.64 Million SEK | 59.229% |
| Lipum AB (publ) | 12.11 Million SEK | -120.999% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 20.353% |
| Nanologica AB (publ) | 77.42 Million SEK | 65.435% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 94.607% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 95.905% |
| AcouSort AB (publ) | 34.51 Million SEK | 22.455% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 87.669% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 65.99% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 90.399% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -33.541% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 96.503% |
| Simris Alg AB (publ) | 174.55 Million SEK | 84.668% |
| Ziccum AB (publ) | 14.97 Million SEK | -78.754% |
| SynAct Pharma AB | 228.01 Million SEK | 88.263% |
| OncoZenge AB (publ) | 20.34 Million SEK | -31.578% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.597% |
| 2cureX AB (publ) | 16.62 Million SEK | -60.98% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -340.398% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 80.965% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -23.315% |
| I-Tech AB | 152.44 Million SEK | 82.444% |
| Cyxone AB (publ) | 43.65 Million SEK | 38.694% |
| Biosergen AB | 7.2 Million SEK | -271.657% |
| Alzinova AB (publ) | 123.18 Million SEK | 78.275% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 88.773% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 68.598% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -216.535% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 69.263% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 6.121% |